Clik here to view.
世界上首款抗衰老健康食品提供商新兴和制药株式会社发布最新的抗衰老研究结果
东京 (美国商业资讯) — 以在全球实现生产性老龄化(productive aging)为目标的新兴和制药株式会社（Shinkowa Pharmaceutical Co., Ltd.，总部：东京都中央区，首席执行官：Megumi Tanaka）已收购博真堂制药株式会社（Hakushindo Pharmaceutical Co.,...
View ArticleClik here to view.
Shinkowa Pharmaceutical, Provider of World’s First Rejuvenative Health Food,...
TOKYO Shinkowa Pharmaceutical Co., Ltd., (Head Office: Chuo-ku, Tokyo, CEO: Megumi Tanaka) whose goal is to achieve productive aging around the world, has acquired all shares of Hakushindo...
View ArticleClik here to view.
LG化学「グローバルイノベーションコンテスト」開催求む！世界を変える革新技術
ソウル韓国 （ビジネスワイヤ） — LG化学(KRX: 051910)が世界を変える革新的な技術の発掘に乗り出す。 同社は、世界有数の大学や研究機関を対象に「グローバルイノベーションコンテスト」(GIC：Global Innovation Contest)を開催することを発表した。 韓国の化学メーカーが世界中から技術を募集するのは今回が初めて。...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Levetiracetam in Sodium...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Levetiracetam in Sodium Chloride Injection, 500...
View ArticleClik here to view.
オクタファルマ、Nuwiq®製剤の新しい有効成分含量が欧州で承認され、血友病A患者に対する投与法の柔軟性が高まると発表
スイス・ラッヘン （ビジネスワイヤ） — オクタファルマは本日、欧州医薬品庁（EMA）が、当社のヒト細胞株由来組み換え型第VIII因子（rF VIII）製剤Nuwiq®に対する市販承認の対象拡大を承認したと発表しました。従来の有効成分含量250、500、1000、2000国際単位（IU）に加え、新たに含量2500、3000、4000 IUの単回用バイアルが欧州で提供可能となります。...
View ArticleClik here to view.
LG化学举办“全球创新大赛 (GIC)”“寻找改变世界的创新技术”
韩国首尔 (美国商业资讯) — LG化学力挺挖掘改变世界的创新技术。 LG化学宣布，以全球大学及研究机构为对象举办“全球创新大赛”(GIC, Global Innovation Contest)。 这是韩国化工企业以全球为对象开展的首次技术征集活动。 LG化学自2018年6月18日到9月30日，在能源、环境、功能材料、生物、平台技术等5大潜力领域征集创新技术方案。...
View ArticleClik here to view.
Octapharma宣布Nuwiq®产品新增剂量规格在欧洲获准，提高了血友病A患者的给药灵活性
瑞士拉亨 (美国商业资讯) — Octapharma今天宣布，该公司人类细胞系衍生重组第VIII因子(rFVIII)产品Nuwiq®已获得欧洲药品管理局(EMA)的新增营销授权。除了现有的250、500、1000、2000国际单位(IU)剂量规格，新增2500、3000、4000 IU单次给药用瓶装剂量规格将在欧洲发售。...
View ArticleClik here to view.
Cerveau Technologies, Inc. Signs Research Agreement with Kobe City Hospital...
BOSTON Cerveau Technologies Inc. today announced an agreement with the Kobe City Hospital Organisation in Japan to support multiple projects over the next several years. These research projects are...
View ArticleClik here to view.
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from...
CASTRES, France Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in...
View ArticleClik here to view.
Clik here to view.
AVITA Medical RECELL® Device Pivotal Trial Results in Second-Degree Burns...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) announced today that results from a pivotal clinical trial demonstrating the effectiveness and clinical benefits of...
View ArticleClik here to view.
SanBio: Summary of Procurement of Funds in the Current Fiscal Year
TOKYO The Group (SanBio Co., Ltd. and its subsidiary SanBio, Inc.) hereby announces procurement of funds totaling ¥11,000 million upon completion of exercise of share acquisition rights with an...
View ArticleClik here to view.
AVITA Medical Announces Presentation of RECELL® Device Clinical Trial Results...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) announced today that results from two U.S. pivotal clinical trials and the U.S. Compassionate Use program...
View ArticleClik here to view.
22ndセンチュリーが非GMO・超低ニコチンの新たな鉄管乾燥タバコ種およびバレー種タバコを発表
米ニューヨーク州ウィリアムズビル （ビジネスワイヤ） — タバコの有害性低減と超低ニコチンタバコでリードする植物バイオテクノロジー企業の22ndセンチュリー・グループ（NYSE American:...
View ArticleClik here to view.
Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide...
SAN DIEGO Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has received $47 million as a result of signing an amendment relating to its OmniAb platform agreement with WuXi Biologics...
View ArticleClik here to view.
AVITA Medical Announces Acquisition of Manufacturing Facility to Support...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that it has entered into an agreement to acquire a manufacturing facility to support the planned...
View ArticleClik here to view.
22nd Century宣布新的非转基因极低尼古丁烤烟和白肋烟变种
纽约州威廉姆斯维尔 (美国商业资讯) — 22nd Century Group, Inc. (NYSE American: XXII) 是一家植物生物技术公司，也是烟草减害和极低尼古丁烟草领域的领导者。公司今天宣布，已从北卡罗莱纳州立大学(NCSU)获得若干种尼古丁含量极低的烤烟和白肋烟植物品系的排他性授权。上述新植物不含外来基因物质（非转基因），将充实22nd...
View ArticleClik here to view.
Daiichi Sankyo and Menarini Enter into Exclusive Licensing Agreement for...
SINGAPORE Singapore based A. Menarini Asia-Pacific Holdings Pte Ltd (“Menarini Asia-Pacific”) and Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) have signed a multi-year exclusive licensing agreement...
View ArticleClik here to view.
Alteogen and Lynkogen Enter into an Exclusive Option Agreement to Develop...
DAEJEON, Korea & EAST WINDSOR, N.J. Alteogen Inc. (KOSDAQ:196170) and Lynkogen Inc. today announced that they have entered into an exclusive option agreement for the development of Alteogen’s...
View ArticleClik here to view.
Takeda Global Headquarters Grand Opening
OSAKA, Japan Takeda Pharmaceutical Company Limited, (“Takeda”) (TOKYO:4502) today held the grand opening of Takeda Global Headquarters. The building, completed in March 2018, will serve as Takeda’s...
View Article